(AUNA) Auna S.A. - Ratings and Ratios

Auna S.A. is a Luxembourg-based healthcare service provider with a significant presence in Latin America, operating hospitals and clinics in Mexico, Peru, and Colombia. The companys diversified healthcare offerings include prepaid healthcare plans in Peru and dental and vision plans in Mexico, positioning it as a comprehensive healthcare solutions provider in the region.

Since its founding in 1989, Auna S.A. has established a strong footprint in the Latin American healthcare market. With its headquarters in Luxembourg, the company is well-positioned to attract international investors. The companys investor relations website (https://www.aunainvestors.com) provides a platform for stakeholders to access information on its financial performance and strategic initiatives.

Analyzing the companys , we observe that the stock is currently trading at $6.86, below its short-term and long-term moving averages (SMA20: $6.96, SMA50: $7.14, SMA200: $7.34). The Average True Range (ATR) of 0.32 indicates a relatively moderate level of price volatility, with a 4.64% daily price swing. The stocks 52-week high and low prices are $9.48 and $6.51, respectively, suggesting a potential support level around $6.50.

From a fundamental perspective, Auna S.A.s indicates a market capitalization of $515.87 million and a price-to-earnings (P/E) ratio of 16.21, which is relatively moderate compared to its peers. The companys return on equity (RoE) stands at 9.81%, indicating a decent level of profitability. However, the absence of a forward P/E ratio makes it challenging to assess the markets expectations for the companys future earnings growth.

Based on the available data, a forecast for Auna S.A.s stock price could be constructed by analyzing the convergence of its technical and fundamental indicators. Given the stocks current price is below its moving averages, and considering the moderate volatility, a potential trading range between $6.50 and $7.50 could be anticipated in the short term. If the company can maintain its RoE and expand its healthcare services, a potential upside could be expected, with a target price of $8.50 in the medium term, representing a 24% increase from the current price.